Coherus BioSciences (CHRS): Partnership Likely in 2H’17 - Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Coherus Biosciences (CHRS) PT Raised to $44 at Maxim Group; 'David Delivers a Blow to Goliath - Humira Patent '135 Falls'
May 17, 2017 7:34 AM EDTMaxim Group raised its price target on Coherus Biosciences (NASDAQ: CHRS) to $44.00 (from $43.00) while maintaining a Buy rating after Humira patent '135 (dosing) has been invalidated.
Analyst Jason McCarthy said with '135 out of the picture, they believe Coherus could be first... More
